PerZeption Receives NEI Grant for Age-Related Macular Degeneration Study
PerZeption Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI). The funding will support the development of a novel diagnostic assessment.
PerZeption Inc. has received a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI). The grant will fund a project focused on developing an efficient method for assessing achromatic and chromatic photostress recovery in age-related macular degeneration (AMD). This initiative aims to improve the early detection and monitoring of the disease.
Age-related macular degeneration is a significant cause of vision loss in older adults. Current diagnostic tools may have limitations in identifying AMD in its early stages. PerZeption's new assessment method is intended to provide a more precise and timely diagnosis.
The SBIR program is a U.S. federal initiative designed to encourage small businesses to commercialize federally funded research and development. The NEI is part of the National Institutes of Health (NIH) and supports research related to eye health and vision.
The company announced the grant award on September 11, 2026. This initial funding will support PerZeption's early-stage research and development efforts to create a new diagnostic tool for the early identification and management of eye conditions.